KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Inventory: 2010-2025

Historic Change in Inventory for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Sep 2025 value amounting to $31.9 million.

  • Jazz Pharmaceuticals' Change in Inventory rose 243.62% to $31.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.4 million, marking a year-over-year increase of 297.53%. This contributed to the annual value of $45.5 million for FY2024, which is 239.36% up from last year.
  • Jazz Pharmaceuticals' Change in Inventory amounted to $31.9 million in Q3 2025, which was up 21.65% from $26.2 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Change in Inventory's 5-year high stood at $35.6 million during Q1 2025, with a 5-year trough of -$816,000 in Q4 2022.
  • For the 3-year period, Jazz Pharmaceuticals' Change in Inventory averaged around $13.9 million, with its median value being $9.3 million (2024).
  • In the last 5 years, Jazz Pharmaceuticals' Change in Inventory slumped by 105.45% in 2022 and then soared by 1,229.42% in 2024.
  • Jazz Pharmaceuticals' Change in Inventory (Quarterly) stood at $15.0 million in 2021, then crashed by 105.45% to -$816,000 in 2022, then spiked by 272.06% to $1.4 million in 2023, then spiked by 1,229.42% to $18.7 million in 2024, then soared by 243.62% to $31.9 million in 2025.
  • Its Change in Inventory stands at $31.9 million for Q3 2025, versus $26.2 million for Q2 2025 and $35.6 million for Q1 2025.